Kisspeptin is not approved by the U.S. FDA for human use and is not lawful to administer to humans. Where it is offered for sale in the U.S., it is sold only as a 'Research Use Only' laboratory chemical, not as a medicine.
Status as of July 15, 2026
Every kisspeptin form traces back to one precursor protein, and the named forms differ mainly in length, not in the part that does the signaling. Kisspeptin-54 and kisspeptin-10 share the identical C-terminal decapeptide that binds the receptor, so both stay fully active in laboratory assays while parting ways on size, stability, and handling. All forms remain unapproved research peptides, not approved therapeutics.
Kisspeptin-54 and kisspeptin-10 both derive from the 145-residue prepro-kisspeptin precursor and share the identical amidated RFamide decapeptide that activates KISS1R, differing chiefly in size (roughly 5.8 versus 1.3 kilodaltons) and circulating stability.
Kisspeptin is the neuropeptide product of the KISS1 gene, expressed mainly in the hypothalamus and translated as a 145-amino-acid precursor called prepro-kisspeptin. The literature first described it as metastin, a metastasis suppressor, before its role as a gatekeeper of reproduction became clear. Proteolytic cleavage of that single precursor at more than one site is what yields several forms, each keeping the conserved C-terminal end responsible for receptor binding.
The KISS1 gene encodes a 145-amino-acid precursor, prepro-kisspeptin, whose enzymatic cleavage releases every kisspeptin form and whose signaling through KISS1R stimulates GnRH, making it essential to puberty and fertility.
The naming looks arbitrary but is literal: each form's number states its exact residue count, so kisspeptin-54 runs 54 amino acids and kisspeptin-10 runs 10. What binds them into one family is a single conserved C-terminal decapeptide, the shared tail ending in the arginine-phenylalanine-amide motif that engages KISS1R.
The precursor yields kisspeptin-54, kisspeptin-14, kisspeptin-13, and kisspeptin-10, named for their residue counts, and all four end in the same conserved arginine-phenylalanine-amide decapeptide that binds KISS1R.
The two forms sit more than five-fold apart in mass, yet they are identical across their final ten residues. Kisspeptin-10 is literally the C-terminal decapeptide of kisspeptin-54, so the whole difference between them is the 44-amino-acid N-terminal extension the larger form carries ahead of that shared tail.
| Property | Kisspeptin-10 | Kisspeptin-54 |
|---|---|---|
| Length | 10 residues | 54 residues |
| Molecular weight | ~1.3 kDa | ~5.8 kDa |
| Shared decapeptide | Entire sequence | C-terminal tail |
| N-terminal extension | None | 44 additional residues |
| C-terminal amidation | Present | Present |
Kisspeptin-10 is the amidated C-terminal decapeptide of kisspeptin-54, identical across the final ten residues, while kisspeptin-54 adds a 44-residue N-terminal extension that raises its mass from roughly 1.3 to 5.8 kilodaltons.
At the receptor itself the two forms are close: both bind KISS1R with broadly comparable affinity in cell-based assays, exactly what the shared C-terminal decapeptide predicts. Where they part is duration in a living system, since the longer-circulating kisspeptin-54 sustains hormone stimulation while the rapidly cleared kisspeptin-10 produces a sharper, shorter response.
Kisspeptin-10 and kisspeptin-54 bind KISS1R with broadly comparable affinity through their shared C-terminal decapeptide, so they diverge less in intrinsic potency than in response duration, with kisspeptin-54 producing more sustained gonadotropin stimulation.
The most consequential difference the literature reports is circulating half-life. Kisspeptin-10 clears within a few minutes, while kisspeptin-54 persists on the order of half an hour, a gap that follows directly from the larger form's size and its N-terminal extension resisting the fast enzymatic trimming that removes the small fragment.
| Pharmacokinetic feature | Kisspeptin-10 | Kisspeptin-54 |
|---|---|---|
| Reported plasma half-life | A few minutes | ~30 minutes |
| Clearance rate | Rapid | Slower |
| Dosing to sustain effect | Continuous infusion or close spacing | Single bolus |
| Basis of the difference | Small, exposed chain | Bulkier, extended structure |
Kisspeptin-10 carries a plasma half-life on the order of only a few minutes versus roughly thirty minutes for kisspeptin-54, so sustaining an effect with kisspeptin-10 generally requires continuous infusion while a single bolus of kisspeptin-54 maintains a longer response.
Both forms are tools of reproductive neuroendocrine research, not approved products, and each tends to be matched to the question a study is asking. The published record uses the short-acting fragment for sharp acute tests and the longer-acting form for protocols needing sustained stimulation, and it consistently frames every such use as investigational rather than therapeutic.
Kisspeptin-10 is typically studied for acute, transient stimulation of the gonadotropin axis while kisspeptin-54 features in investigational human fertility-related studies, but both are unapproved research peptides and neither is an authorized treatment.
As unapproved research peptides, kisspeptin forms carry stability risks that can quietly distort results, and their safety record is limited. Because the arginine-phenylalanine-amide terminus is essential for activity, any degradation reaching the C-terminal region erodes potency, and the human safety data that exist come only from small, short-term investigational studies.
Kisspeptin forms are unapproved research peptides whose activity depends on an intact arginine-phenylalanine-amide terminus, so freeze-thaw cycles, warmth, and time in solution can degrade potency, and their limited short-term human safety data do not establish a profile for therapeutic use.
Educational use only. This article describes what the published scientific and clinical literature reports about Kisspeptin. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
